Completed PHASE3 INTERVENTIONAL 3-arm NCT01497002

Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a (AML2004)

Randomized Phase III Study Comparing the OSHO Arm to the Standard Intergroup Arm.

Sponsor: University of Leipzig

Interventions Cytarabine human stem cells

Updated 7 times since 2017 Last updated: Jan 30, 2024 Started: Apr 30, 2005 Primary completion: Jul 18, 2018 Completion: Jul 18, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01497002, this PHASE3 trial focuses on Acute Myeloid Leukaemia and remains completed. Sponsored by University of Leipzig, it has been updated 7 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Feb 2024 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Feb 2024 [monthly]

Completed PHASE3
Feb 2020 — Jan 2021 [monthly]

Completed PHASE3

Status: Unknown Status → Completed

▶ Show 2 earlier versions

Jun 2018 — Feb 2020 [monthly]

Unknown Status PHASE3
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Leipzig

Data source: University of Leipzig

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Leipzig, Germany